Variant sequences: the new frontier in sequence IP

A variant sequence is typically a naturally-occurring molecule, most frequently protein, which has been modified in order to impart desired characteristics such as improved stability under anticipated use conditions, or increased activity. Optimising sequences and, of course, the associated IP rights, span most areas of biotechnology.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Exelixis opens two-front patent dispute over Cabometyx copies

9 July 2026 Separate lawsuits target Indian and Taiwanese pharma companies as Exelixis seeks to keep rival cabozantinib products off the US market until key patents expire.

Europe

UPC upholds injunction in Invisalign maker’s software dispute with rival

9 July 2026 China-headquartered Angelalign failed to convince UPC appellate judges to overturn a ban that affects its ability to offer orthodontic planning software in Europe with certain functionality.

Europe

BioNTech and Pfizer secure big European win over mRNA patent

8 July 2026 UPC judges revoke a patent asserted against the companies over their Comirnaty COVID-19 vaccine, in a ruling that clarified the court’s key principles on exclusive licences, novelty and inventive step.

More features

BioNTech and Pfizer secure big European win over mRNA patent

UPC revives patent, but timing sinks Guardant’s appeal

HGF expands European offering with pair of in-house hires

King & Spalding continues hiring spree from pre-merged Winston

Insilico lands potential $2.5bn AI biotech partnership

US life sciences damages averaged $33.5m between 2019-2025

Court upholds $83m sequencing verdict and sets royalty rate

Amgen and subsidiary dealt $20m blow over rodent antibody tech

Variant sequences: the new frontier in sequence IP

More on this story

Editor's picks

Editor's picks

More features